HEALTH PROFESSIONAL · SOURCE READING

HDAC inhibitor therapy

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer

Epigenetic modification alters gene expression. This can lead to endocrine therapy resistance and may be reversed by epigenetic modifiers such as histone deacetylase (HDAC) inhibitors. Entinostat, an oral HDAC inhibitor, induces downregulation of estrogen-independent growth factor signaling pathways and normalization of estrogen receptor levels. Entinostat was evaluated in a phase III trial and showed no benefit.[35,36]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice